Daan J. A. Crommelin
AuthID: R-007-2KD
1
TITLE: The regulator's perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future? Full Text
AUTHORS: Daan J A Crommelin; Karl Broich; Chris Holloway; Bianca Meesen; Jana Lizrova Preiningerova; Jean Louis Prugnaud; Beatriz Silva Lima;
PUBLISHED: 2016, SOURCE: MULTIPLE SCLEROSIS JOURNAL, VOLUME: 22, ISSUE: 2 Suppl
AUTHORS: Daan J A Crommelin; Karl Broich; Chris Holloway; Bianca Meesen; Jana Lizrova Preiningerova; Jean Louis Prugnaud; Beatriz Silva Lima;
PUBLISHED: 2016, SOURCE: MULTIPLE SCLEROSIS JOURNAL, VOLUME: 22, ISSUE: 2 Suppl
2
TITLE: How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider
AUTHORS: Huub Schellekens; Sven Stegemann; Vera Weinstein; Jon S B de Vlieger; Beat Fluehmann; Stefan Muehlebach; Rogerio Gaspar; Vinod P Shah; Daan J A Crommelin;
PUBLISHED: 2014, SOURCE: AAPS JOURNAL, VOLUME: 16, ISSUE: 1
AUTHORS: Huub Schellekens; Sven Stegemann; Vera Weinstein; Jon S B de Vlieger; Beat Fluehmann; Stefan Muehlebach; Rogerio Gaspar; Vinod P Shah; Daan J A Crommelin;
PUBLISHED: 2014, SOURCE: AAPS JOURNAL, VOLUME: 16, ISSUE: 1
3
TITLE: Scientific considerations for complex drugs in light of established and emerging regulatory guidance. Scientific considerations for complex drugs Full Text
AUTHORS: Chris Holloway; Jan Mueller Berghaus; Beatriz Silva Lima ; Sau (Larry) Lee; Janet S Wyatt; Michael M Nicholas; Daan J A Crommelin;
PUBLISHED: 2012, SOURCE: ANNALS MEETING REPORTS 2013, VOLUME: 1276, ISSUE: 1
AUTHORS: Chris Holloway; Jan Mueller Berghaus; Beatriz Silva Lima ; Sau (Larry) Lee; Janet S Wyatt; Michael M Nicholas; Daan J A Crommelin;
PUBLISHED: 2012, SOURCE: ANNALS MEETING REPORTS 2013, VOLUME: 1276, ISSUE: 1
